Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcutaneous Administration in Healthy Volunteers/Overweight or Obese Volunteers

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 9, 2025

Primary Completion Date

June 6, 2026

Study Completion Date

October 10, 2026

Conditions
Healthy
Interventions
DRUG

ZT003

ZT003 is administered as a single subcutaneous injection at different dose levels.

DRUG

ZT003

ZT003 administered as multiple subcutaneous injections at different dose levels.

DRUG

Placebo

Matching placebo administered subcutaneously.

Trial Locations (1)

Unknown

Nucleus Network Brisbane, Brisbane

All Listed Sponsors
lead

Beijing QL Biopharmaceutical Co.,Ltd

INDUSTRY